DeutschNewstral
Article
jdsupra.com on 2021-05-01 01:30
PMPRB update: Revised compliance timelines for grandfathered and gap medicines and proposed regulatory amendments directed to CSPs
Related news
- PMPRB Update: Jurisdiction extends to CSPs effective June 30; coming into force of Patented Medicines Regulations and Guidelines delayed to January 2022jdsupra.com
- PMPRB Updates: Definition of “Gap Medicine” amended, modified threshold for investigating the price of new patented medicinesjdsupra.com
- Drug pricing in Canada: Changes for the PMPRB with proposed amendments to the Patented Medicines Regulationsjdsupra.com
- Amendments to PMPRB Regulations will now be in force January 1, 2021jdsupra.com
- PMPRB proposes to modify Guidelines definition of "gap medicine" to include medicines sold by July 1, 2021jdsupra.com
- Slam dunk! New basket of countries for PMPRB reporting remain, controversial amendments to Patented Medicines Regulations droppedjdsupra.com
- Few significant changes made in final PMPRB Guidelinesjdsupra.com
- 2021 PMPRB Annual Reportjdsupra.com
- PMPRB releases draft Guidelines operationalizing amended Patented Medicines Regulationsjdsupra.com
- PMPRB releases three new NPDUIS reportsjdsupra.com
- PMPRB publishes annual Meds Pipeline Monitor reportjdsupra.com
- New PMPRB Guidelines will not be implemented January 1, 2023jdsupra.com
- PMPRB Update: new consultation on PMPRB Guidelines, including revised international price testsjdsupra.com
- Amendments to PMPRB Regulations will now be in force July 1, 2021jdsupra.com
Timelinesnorthcoastjournal.com- KEBA submits over 500 amendments to bill on medicinesKyivPost
- PMPRB releases 2020 Annual Report and April 2022 NEWSletterjdsupra.com
- PMPRB adopts Amended Interim Guidance pending release of new guidelinesjdsupra.com
- Innovators challenge final PMPRB Guidelines in new Federal Court applicationjdsupra.com
- FCA remits pricing decision on ALEXION’S SOLIRIS to PMPRBjdsupra.com